Why not?
By then they should have 2 drugs in market with U$3B revenue at 90% margins and another $10B one close...plus any others added in the interim. $12B at 90% = $10.8B net revenue - less overheads (relatively minor) and at say 10x PE would give the co a market cap of circa $108B.
OK, so all may not make it, revenue might not be as much as advertised, risks need to be factored in etc....but no doubt the potential is there and $35B is around 1/3 of that potential.
So, again, why not?
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.20 |
Change
0.040(3.45%) |
Mkt cap ! $699.9M | |||
| Open | High | Low | Value | Volume |
| $1.19 | $1.20 | $1.18 | $97.44K | 81.86K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5000 | $1.18 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.20 | 19651 | 3 |
View Market Depth
| Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |